Otolith Labs Pitch Deck: All 11 Slides + Teardown

Otolith Labs: A Clinical Approach to Medical Hardware

Otolith Labs entered the Series A market with a clear objective: to transition from an experimental hardware startup to a clinically validated medical device company. As reported by Business Insider, the company raised $20 million in 2024. The deck they used is remarkably concise at 11 slides, focusing heavily on the 'why' and the 'how' of their vestibular masking technology rather than traditional business metrics. In a sector like biotech and medical hardware, the strength of the clinical argument often outweighs the immediate revenue figures, and this deck reflects that hierarchy of information.

Slide 1: The Visual Hook

The opening slide features a high-resolution profile shot of a woman wearing the Otolith device. The device itself is a small, black, oblong pod attached to a simple black headband, positioned just behind the ear. The text is minimal: 'Otolith Labs' experimental, wearable device to treat vertigo.' By leading with a lifestyle-style photograph rather than a technical schematic, the company immediately establishes that this is a wearable, non-invasive solution. It humanizes the technology before diving into the medical complexities.

Slide 2: Simple, Protected, Breakthrough

Slide 2 serves as the primary value proposition slide. It uses three powerful adjectives in the header: 'SIMPLE, PROTECTED, BREAKTHROUGH.' The slide lists five key bullet points: Precise Level of Therapeutic Vibration, Vertiginous Vestibular Signals Are Masked and Alleviated, Patented, Reliable & Durable 5th-Generation Model, and FDA Breakthrough Designation. The inclusion of an anatomical diagram of the inner ear, showing vibration waves entering the vestibular system, provides immediate context for how the device functions. The mention of the '5th-Generation Model' is a subtle but important signal to investors that the $20M raise isn't for basic prototyping; the hardware has already been through multiple iterations.

Slide 4: The Clinical Path Problem

One of the most effective slides in the deck is Slide 4, 'CURRENT PATIENT CLINICAL PATH.' It maps out the frustrating journey of a vertigo sufferer. It starts at 'First Onset' (Primary Care/ER), moves to 'ENT' where they are often prescribed 'Antivert,' and then enters a loop labeled 'x5' between ENTs and specialists like Physical Therapists and Neurologists. The final stage is 'Self-Care Expert,' which is a polite way of saying the medical system failed the patient. This slide identifies the market gap: a lack of effective, immediate treatment that prevents the expensive and time-consuming specialist loop.

Slide 6: Product Benefits and Scalability

Slide 6 repeats the 'SIMPLE, PROTECTED, BREAKTHROUGH' header but changes the bullet points to focus on patient outcomes and future potential. It claims the device 'Works Immediately,' 'Lasts Indefinitely,' and has 'No Known Side Effects.' The most interesting point for a venture capitalist is the final one: 'Can Be Integrated Into Most Headworn Wearables.' This suggests that Otolith Labs isn't just a headband company; they are a vestibular technology company that could eventually partner with giants in the consumer electronics or VR space to solve motion sickness at scale.

Slide 8: Leadership and Domain Expertise

The leadership slide (Slide 8) is designed to build technical credibility. Sam Owen is credited as the inventor of the technology. However, the 'anchor' for medical investors is likely Didier Depireux, Ph.D., the Chief Science Officer, who brings 25 years of faculty experience from the UMD School of Medicine as an 'Inner Ear Expert.' The presence of Jon Akers (CPO) with '20+ Hardware Products Launched' addresses the common investor fear that scientists can't handle the complexities of mass manufacturing hardware.

Slide 11: The Brand Identity

The final slide is a simple presentation of the Otolith logo—a series of concentric blue semi-circles resembling sound or vibration waves. While it contains no new data, it reinforces the brand's focus on 'vibration' as the core modality of their treatment. The simplicity of the deck's design—lots of white space, clear orange and blue accents—mirrors the 'Simple' part of their three-word mantra.

What Otolith Labs Does Well

The deck excels at regulatory signaling . In the world of medical devices, an FDA Breakthrough Designation is a massive de-risking event. By placing this on Slide 2, Otolith immediately separates itself from 'wellness' wearables that lack clinical backing. The deck also does a fantastic job of visualizing the pain point . Slide 4 doesn't just say 'vertigo is hard to treat'; it shows the specific, repetitive clinical failures that cost the healthcare system money and patients their quality of life.

Furthermore, the hardware maturity is emphasized. Many hardware pitches fail because the device looks like a science project. By showing a sleek, wearable form factor on Slide 1 and mentioning the 5th-generation iteration on Slide 2, they communicate that the engineering risk is largely behind them, and the Series A capital will likely be used for clinical trials and commercialization.

What is Missing from the Deck

The most glaring omission is a detailed 'Ask' slide . While we know from external reporting that they raised $20M, the deck itself does not specify the amount sought or the specific milestones that capital will achieve (e.g., 'Fund Phase III trials,' 'Scale manufacturing to 10k units').

There is also a total lack of market sizing (TAM) . While vertigo is a known issue, investors generally want to see the specific number of chronic sufferers and the projected revenue per user. Similarly, there is no financial roadmap . We don't see projected burn rates, margins on the hardware, or a timeline to profitability. In a Series A deck, these omissions are unusual and suggest that the clinical and regulatory story was so compelling that the 'business' metrics were handled in a separate data room or follow-up meetings.

Lessons for Founders

Lead with your strongest 'Trust Signal': If you have a patent, a major regulatory win (like FDA Breakthrough), or a world-class expert on the team, put it on the first three slides. Don't bury the lead. · Visualize the 'Status Quo' failure: Don't just list your features. Show the current, broken process your customers have to endure. If you can show a 'loop of failure' that your product breaks, you've won the emotional argument. · Address the 'Hardware is Hard' stigma: If you are building a physical product, explicitly mention which 'generation' of the prototype you are on. Showing that you have iterated through five versions tells investors you have already solved the early, most common engineering hurdles. · Position for the 'Platform' play: Even if you are launching a single product, show how that technology could be used elsewhere. Otolith's mention of integration into other wearables turns a niche medical device into a potential horizontal technology play.